Paul Gulden manages the Pax World Growth Fund and has studied which stocks will win and lose from this giant new program. He joins us from New York.
GULDEN: Well, I have mentioned them in the past. I wouldn't say that necessarily they are necessarily the major beneficiary here, but some of the other offshoot companies are. For instance, the companies that deal with outcomes analysis, which is sort of a word that's thrown around. It's better medical care, as an example. There's a company called American Healthways which we do own in the fund which I think is quite interesting. They effectively take over disease management programs for the HMOs and the hospitals for sustaining diseases, if you will. Diabetes would be a good example. A very difficult program to administer, and they are experts in doing so.
Which would you rather believe? An analyst's "opinion" who has no monetary stake in the company, and may be serving unseen constituents? Or a portfolio manager who puts his reputation and money on the line for the public to see?